Acute Central Nervous System Complications in XXXX .

@entity1 @entity1032 @entity981 @entity5892 @entity75 @entity16 @entity149 @entity1897 @entity1778 @entity364 @entity302 @entity1499 @entity6085
BACKGROUND: The outcome of childhood @entity981 has improved because of intensive chemotherapy and supportive care. The frequency of adverse events has also increased, but the data related to @entity149 during @entity981 treatment are sparse. The purpose of this study is to evaluate these complications and to determine their long term outcome. @entity1 AND METHODS: We retrospectively analyzed the hospital reports of 323 @entity1 with de novo @entity981 from a 13-year period for acute @entity16 . The @entity149 of @entity1778 , @entity1897 , and post-treatment late-onset @entity75 , and @entity149 were excluded. RESULTS: Twenty-three of 323 @entity1 (7.1%) suffered from @entity149 during @entity981 treatment. The majority of these complications (n = 13/23; 56.5%) developed during the induction period. The complications included posterior reversible @entity75 (n = 6), @entity364 (n = 5), @entity75 (n = 5), @entity6085 (n = 4), and @entity1499 @entity75 (n = 3). Three of these 23 @entity1 (13%) died of @entity149 , one from an intracranial @entity364 and the others from @entity5892 . Seven of the survivors (n = 7/20; 35%) became @entity302 and three of them had also developed @entity1032 . CONCLUSIONS: @entity149 are varied and require an urgent approach for proper diagnosis and treatment. Collaboration among the hematologist, radiologist, neurologist, microbiologist, and neurosurgeon is essential to prevent fatal outcome and serious morbidity.
